Detalhe da pesquisa
1.
A Circulating Panel of circRNA Biomarkers for the Noninvasive and Early Detection of Pancreatic Ductal Adenocarcinoma.
Gastroenterology
; 166(1): 178-190.e16, 2024 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-37839499
2.
Targeting LIF-mediated paracrine interaction for pancreatic cancer therapy and monitoring.
Nature
; 569(7754): 131-135, 2019 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-30996350
3.
First-in-Human Phase I Study of Minnelide in Patients With Advanced Gastrointestinal Cancers: Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity.
Oncologist
; 29(2): 132-141, 2024 Feb 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-38169017
4.
An Exosome-based Transcriptomic Signature for Noninvasive, Early Detection of Patients With Pancreatic Ductal Adenocarcinoma: A Multicenter Cohort Study.
Gastroenterology
; 163(5): 1252-1266.e2, 2022 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-35850192
5.
Author Correction: Targeting LIF-mediated paracrine interaction for pancreatic cancer therapy and monitoring.
Nature
; 600(7889): E18, 2021 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-34848876
6.
A Phase Ib Study of Single-Agent Idelalisib Followed by Idelalisib in Combination with Chemotherapy in Patients with Metastatic Pancreatic Ductal Adenocarcinoma.
Oncologist
; 25(11): e1604-e1613, 2020 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-32356383
7.
An Analysis of Patients with DNA Repair Pathway Mutations Treated with a PARP Inhibitor.
Oncologist
; 25(1): e60-e67, 2020 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31391296
8.
A Phase II, Single-Arm, Open-Label, Bayesian Adaptive Efficacy and Safety Study of PBI-05204 in Patients with Stage IV Metastatic Pancreatic Adenocarcinoma.
Oncologist
; 25(10): e1446-e1450, 2020 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-32452588
9.
Family communication and patient distress after germline genetic testing in individuals with pancreatic ductal adenocarcinoma.
Cancer
; 125(14): 2488-2496, 2019 07 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-30980401
10.
A Phase 1b/2 Study of the Bruton Tyrosine Kinase Inhibitor Ibrutinib and the PD-L1 Inhibitor Durvalumab in Patients with Pretreated Solid Tumors.
Oncology
; 97(2): 102-111, 2019.
Artigo
em Inglês
| MEDLINE | ID: mdl-31230047
11.
Use of Precision Imaging in the Evaluation of Pancreas Cancer.
Cancer Treat Res
; 178: 209-236, 2019.
Artigo
em Inglês
| MEDLINE | ID: mdl-31209847
12.
Prospective study of germline genetic testing in incident cases of pancreatic adenocarcinoma.
Cancer
; 124(17): 3520-3527, 2018 09 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30067863
13.
Choroidal metastasis of pancreatic adenocarcinoma: case report.
AME Case Rep
; 8: 22, 2024.
Artigo
em Inglês
| MEDLINE | ID: mdl-38234350
14.
Results of a Randomized, Double-Blind, Placebo-Controlled, Phase 1b/2 Trial of Nabpaclitaxel + Gemcitabine ± Olaratumab in Treatment-Naïve Participants with Metastatic Pancreatic Cancer.
Cancers (Basel)
; 16(7)2024 Mar 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-38611000
15.
Malignant ascites in pancreatic cancer: Pathophysiology, diagnosis, molecular characterization, and therapeutic strategies.
Front Oncol
; 13: 1138759, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37007072
16.
A rare case of sporadic mismatch repair deficient pancreatic ductal adenocarcinoma that responded to ipilimumab and nivolumab combination treatment: case report.
J Gastrointest Oncol
; 14(1): 458-462, 2023 Feb 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-36915432
17.
A super-enhancer-regulated RNA-binding protein cascade drives pancreatic cancer.
Nat Commun
; 14(1): 5195, 2023 09 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-37673892
18.
Overcoming Taxane Resistance: Preclinical and Phase 1 Studies of Relacorilant, a Selective Glucocorticoid Receptor Modulator, with Nab-Paclitaxel in Solid Tumors.
Clin Cancer Res
; 28(15): 3214-3224, 2022 08 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-35583817
19.
Mitomycin C in Homologous Recombination Deficient Metastatic Pancreatic Cancer after Disease Progression on Platinum-Based Chemotherapy and Olaparib.
Biomedicines
; 10(11)2022 Oct 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-36359225
20.
Tilsotolimod Exploits the TLR9 Pathway to Promote Antigen Presentation and Type 1 IFN Signaling in Solid Tumors: A Multicenter International Phase I/II Trial (ILLUMINATE-101).
Clin Cancer Res
; 28(23): 5079-5087, 2022 12 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35917516